GlassScriptPhysician profile
Luis J Dlouhy
NPI 1477907434
$12,187.26
in general payments reported to CMS, 2019-2025
20 companies · $836 in 2025
The $836 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.84 · 2021: $351 · 2022: $4,784 · 2023: $4,410 · 2024: $1,791 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,378 · Travel and Lodging: $1,451 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,378.11 |
| Travel and Lodging | $1,451.00 |
| Education | $208.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $8,161.33 | 2021-2025 | Ensite Precision, Cardiomems, Gallant |
| Boston Scientific Corporation | $1,508.80 | 2022-2024 | Rhythmia Mapping System, Synergy, Ilab Ultrasound Imaging System |
| Medtronic, INC. | $497.94 | 2022-2024 | Venaseal, Cobalt Dr Mri Surescan, Percepta Quad Crt-P Mri Surescan |
| Shockwave Medical, INC | $348.05 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Inari Medical, INC. | $270.65 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $245.02 | 2020-2025 | Repatha, Repatha |
| Philips North America LLC | $236.97 | 2023-2024 | (Bh4) Igt Devices Undivided |
| Cardiva Medical, INC. | $207.80 | 2022-2023 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Abiomed | $143.47 | 2024 | Impella |
| Cordis US Corp. | $120.27 | 2024 | Mynx Control, Mynxgrip |
| Tactile Systems Technology INC | $69.33 | 2025 | Nimbl, Flexitouch Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.79 | 2024-2025 | Jardiance |
| Scpharmaceuticals INC. | $59.02 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.27 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $45.75 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $40.90 | 2023-2025 | Kengreal, Cleviprex |
| Astrazeneca Pharmaceuticals LP | $33.32 | 2025 | Farxiga |
| Bridgebio Pharma, INC. | $32.65 | 2025 | Attruby |
| Inspire Medical Systems, INC. | $31.92 | 2025 | Inspire |
| Pfizer INC. | $23.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Dlouhy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.